Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV
Sznajderman, M.
Przeglad Lekarski 41(7): 493-499
1984
ISSN/ISBN: 0033-2240 PMID: 6390536 Document Number: 225109
Document emailed within 1 workday
Related Documents
Bolzano, K.; Krempler, F.; Schellenberg, B.; Schlierf, G. 1979: A comparison of bezafibrate and clofibrate in type Ii B and type IV hyperlipoproteinemia Acta Medica Austriaca 6(3): 90-94Arntz, H.R.; Klemens, U.H.; Vollmar, L.J.; Lang, P.D. 1978: Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia Medizinische Klinik 73(49): 1731-1737
Schwartzkopff, W.; Luley, C.; Scheffler, W.; Lehmann-Leo, W.; Schilling, A.; Wegscheider, K. 1982: Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV Die Medizinische Welt 33(17): 631-637
Kowalski, J.; Okopien, B.; Madej, A.; Zielinski, M.; Belowski, D.; Kalina, Z.; Herman, Z.S. 2003: Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia International Journal of Clinical Pharmacology and Therapeutics 41(6): 241-247
Borowska, A.; Bachórzewska-Gajewska, H.; Kaliciński, A. 1986: Platelet aggregation in patients with hyperlipoproteinemia treated with bezafibrate Polski Tygodnik Lekarski 41(9): 273-276
Ceska, R.; Stulc, T. 2000: Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic Casopis Lekaru Ceskych 139(12): 369-373
Micheli, H.; Pometta, D.; Gustafson, A. 1980: Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins a and B in type IIa HLP La Nouvelle Presse Medicale 9(49): 3759-3762
Denmacker, P.N.; Vos-Janssen, H.E.; Stuyt, P.M.; Schade, R.W.; Jansen, A.P.; van 't Laar, A. 1978: Application and comparison of different criteria used for the diagnosis of type IIi hyperlipoproteinemia Clinical Chemistry 24(9): 1445-1451
Manojlović, D.; Lepsanović, L.; Micić, D.; Sumarac, M.; Kendereski, L.; Popović, V.; Mićić, J. 1991: Multicenter study of the efficacy and tolerance of gemfibrozil and fenofibrate in the treatment of primary hyperlipoproteinemia Srpski Arhiv Za Celokupno Lekarstvo 119(1-2): 22-25
Kokot, F.; Szczechowska, E. 1981: Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 36(13): 454-457
Vílchez Joya, R.; Escobar Jiménez, F.; Campos, M.M.; Torres, E.; Orduña, R.; Cabrera, J.; Núñez, J. 1986: Effects of bezafibrate in patients with combined hyperlipidemia Medicina Clinica 86(5): 190-194
Adam, O.; Wolfram, G.; Lang, P.D.; Zöllner, N. 1979: Dose-effects studies with bezafibrate in patients with hypercholesterolemia and hypertriglyceridemia Münchener Medizinische Wochenschrift 121(9): 319-322
Okopień, B.ła.; Cwalina, Łu.; Haberka, M.; Kowalski, J.; Zieliński, M.; Szwed, Z.; Kalina, Z.; Herman, Z.S. 2002: Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 13(78): 465-469
Mikheev, G.N.; Smirnov, A.V.; Sazonets, G.I.; Kozhevnikov, A.D. 1986: Use of entero-and hemosorption in a patients with diabetic xanthomatosis and hyperlipoproteinemia type V Klinicheskaia Meditsina 64(11): 132-134
Broncel, M.; Cieślak, D.; Koter-Michalak, M.; Duchnowicz, P.; Mackiewicz, K.; Chojnowska-Jezierska, J. 2006: The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 20(119): 547-550
Klemens, U.H.; Bremer, A.; von Wnuck, E.; von Löwis, P. 1972: Frequency of hyperlipoproteinemia with type distribution in patients with myocardial infarct and agina pectoris Zeitschrift für Ernahrungswissenschaft. Journal of Nutritional Sciences. Supplementa 12: Suppl 12: 61-67
Kotsiumbas, E.M. 1986: Relation between platelet aggregation in ischemic heart disease patients and the type of hyperlipoproteinemia Klinicheskaia Meditsina 64(1): 72-74
Mertz, D.P.; Loewer, H.; Suermann, I. 1979: The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa Medizinische Klinik 74(51-52): 1953-1956
Haacke, H.; Parwaresch, M.R.; Mäder, C. 1976: The effect of xanthinol nicotinate on the serum lipids and lipoproteins of patients with primary hyperlipoproteinemia Type IIb and IV Verhandlungen der Deutschen Gesellschaft für Innere Medizin 82 Pt 1: 829-832
Jäger, E.; Sinzinger, H.; Widhalm, K.; Kaliman, J.; Höfer, R. 1982: Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis Wiener Klinische Wochenschrift 94(16): 421-425